OBJECTIVE: To determine the life expectancy of patients with Parkinson disease (PD) in the United States and identify demographic, geographic, and clinical factors that influence survival. DESIGN: Retrospective cohort study of 138 000 Medicare beneficiaries with incident PD who were identified in 2002 and followed up through 2008. MAIN OUTCOME MEASURES: Confounder-adjusted 6-year risk of death as influenced by 3 groups of factors: (1) race, sex, and age at diagnosis; (2) geography and environmental factors; and (3) clinical conditions. We examined hospitalization diagnoses in patients with terminal PD and compared PD mortality with that of other common diseases. RESULTS: Thirty-five percent of patients with PD lived more than 6 years. Sex and race significantly predicted survival; patients who were female (HR [hazard ratio], 0.74; 95% CI, 0.73-0.75), Hispanic (HR, 0.72; 95% CI, 0.65-0.80), or Asian (HR, 0.86; 95% CI, 0.82-0.91) had a lower adjusted risk of death than white men. Dementia, diagnosed in 69.6% of cases and most often in African American patients (78.2%) and women (71.5%), was associated with a greater likelihood of death (HR, 1.72; 95% CI, 1.69-1.75). Parkinson disease mortality was greater than that of many common life-threatening diseases. Patients with terminal PD were hospitalized frequently for cardiovascular disease (18.5%) and infection (20.9%) but rarely for PD (1.0%). Regional survival rates were similar but patients with PD living in urban high industrial metal emission areas had a slightly higher adjusted risk of death (HR, 1.19; 95% CI, 1.10-1.29). CONCLUSIONS: Demographic and clinical factors impact PD survival. Dementia is highly prevalent in patients with PD and is associated with a significant increase in mortality. More research is needed to understand whether environmental exposures influence PD course or survival.
OBJECTIVE: To determine the life expectancy of patients with Parkinson disease (PD) in the United States and identify demographic, geographic, and clinical factors that influence survival. DESIGN: Retrospective cohort study of 138 000 Medicare beneficiaries with incident PD who were identified in 2002 and followed up through 2008. MAIN OUTCOME MEASURES: Confounder-adjusted 6-year risk of death as influenced by 3 groups of factors: (1) race, sex, and age at diagnosis; (2) geography and environmental factors; and (3) clinical conditions. We examined hospitalization diagnoses in patients with terminal PD and compared PDmortality with that of other common diseases. RESULTS: Thirty-five percent of patients with PD lived more than 6 years. Sex and race significantly predicted survival; patients who were female (HR [hazard ratio], 0.74; 95% CI, 0.73-0.75), Hispanic (HR, 0.72; 95% CI, 0.65-0.80), or Asian (HR, 0.86; 95% CI, 0.82-0.91) had a lower adjusted risk of death than white men. Dementia, diagnosed in 69.6% of cases and most often in African American patients (78.2%) and women (71.5%), was associated with a greater likelihood of death (HR, 1.72; 95% CI, 1.69-1.75). Parkinson diseasemortality was greater than that of many common life-threatening diseases. Patients with terminal PD were hospitalized frequently for cardiovascular disease (18.5%) and infection (20.9%) but rarely for PD (1.0%). Regional survival rates were similar but patients with PD living in urban high industrial metal emission areas had a slightly higher adjusted risk of death (HR, 1.19; 95% CI, 1.10-1.29). CONCLUSIONS: Demographic and clinical factors impact PD survival. Dementia is highly prevalent in patients with PD and is associated with a significant increase in mortality. More research is needed to understand whether environmental exposures influence PD course or survival.
Authors: Allison W Willis; Bradley A Evanoff; Min Lian; Aiden Galarza; Andrew Wegrzyn; Mario Schootman; Brad A Racette Journal: Am J Epidemiol Date: 2010-10-19 Impact factor: 4.897
Authors: Allison Wright Willis; Bradley A Evanoff; Min Lian; Susan R Criswell; Brad A Racette Journal: Neuroepidemiology Date: 2010-01-15 Impact factor: 3.282
Authors: Marwan N Sabbagh; Charles H Adler; Tyson J Lahti; Donald J Connor; Linda Vedders; Lars K Peterson; John N Caviness; Holly A Shill; Lucia I Sue; Iryna Ziabreva; Elaine Perry; Clive G Ballard; Dag Aarsland; Douglas G Walker; Thomas G Beach Journal: Alzheimer Dis Assoc Disord Date: 2009 Jul-Sep Impact factor: 2.703
Authors: Marc G Weisskopf; Jennifer Weuve; Huiling Nie; Marie-Helene Saint-Hilaire; Lewis Sudarsky; David K Simon; Bonnie Hersh; Joel Schwartz; Robert O Wright; Howard Hu Journal: Environ Health Perspect Date: 2010-11 Impact factor: 9.031
Authors: Richard A Armstrong; Paul T Kotzbauer; Joel S Perlmutter; Meghan C Campbell; Kyle M Hurth; Robert E Schmidt; Nigel J Cairns Journal: J Neural Transm (Vienna) Date: 2013-08-31 Impact factor: 3.575
Authors: Grace S Hwang; Monica T Young; Mark H Hanna; Gopal Menon; Michael Phelan; Joseph C Carmichael; Steven Mills; Michael J Stamos; Neal Hermanowicz; Alessio Pigazzi Journal: Int J Colorectal Dis Date: 2015-06-04 Impact factor: 2.571
Authors: Paul T Kotzbauer; Nigel J Cairns; Meghan C Campbell; Allison W Willis; Brad A Racette; Samer D Tabbal; Joel S Perlmutter Journal: Arch Neurol Date: 2012-10
Authors: Albert A Davis; Casey E Inman; Zachary M Wargel; Umber Dube; Brittany M Freeberg; Alexander Galluppi; Jessica N Haines; Dhruva D Dhavale; Rebecca Miller; Fahim A Choudhury; Patrick M Sullivan; Carlos Cruchaga; Joel S Perlmutter; Jason D Ulrich; Bruno A Benitez; Paul T Kotzbauer; David M Holtzman Journal: Sci Transl Med Date: 2020-02-05 Impact factor: 17.956
Authors: Allison W Willis; Mario Schootman; Nathan Kung; Xiao-Yu Wang; Joel S Perlmutter; Brad A Racette Journal: Neurology Date: 2013-12-11 Impact factor: 9.910